Join The Club: Alnylam Signs On Takeda In RNAi Platform Deal

 
• By Jessica Merrill

Takeda gains non-exclusive access to Alnylam’s RNAi therapeutics platform in oncology and metabolic disease for $150 million upfront.

More from Archive

More from Pink Sheet